$LABT News

HC Wainwright & Co. Initiates Coverage On Lakewood-Amedex with Buy Rating, Announces Price Target of $3

Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates

LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms

Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders

Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood Amedex Has Received A Notice Of Allowance For A U.S. Patent Titled "ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF".

LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company